Drug intelligence / Profile preview

BDR-131

Development stage: Unknown
Lead developer: Caravan Biologix
Modality: Cell Therapies, Gene Therapies, Nanoparticles → Drug Delivery Systems
Administration: Parenteral

Overview

BDR-131 is a novel therapeutic candidate in early research, developed through a collaboration between Caravan Biologix and MDimune. It is being investigated as an antineoplastic agent for cancer, specifically solid tumors. The therapeutic approach involves chimeric antigen receptor natural killer (CAR-NK) cell therapies delivered via bionanovesicles, aiming to leverage immunologic cytotoxicity and natural killer cell replacements to combat cancer. It is currently in early research stages in the USA, with parenteral administration.

Beyond the preview

Go deeper on BDR-131.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BDR-131.

Explore the full profile